A virtual roundtable discussion with noted investigators Dr Toni
K Choueiri and Prof Thomas Powles for a review of recent
innovations in the treatment of renal cell carcinoma.
Risk stratification and selection of first-line therapy for
metastatic renal cell carcinoma (mRCC) (00:00)
Role of cytoreductive nephrectomy in RCC (1:50)
Overall survival and complete response (CR) improvements with
the FDA-approved nivolumab/ipilimumab combination versus sunitinib
for intermediate- or poor-risk previously untreated advanced RCC on
the Phase III CheckMate 214 trial (4:18)
Activity of nivolumab alone or in combination with ipilimumab
for patients with mRCC and brain metastases (9:25)
Tolerability of nivolumab/ipilimumab; risk of immune-related
adverse events (AEs) (11:21)
Recent FDA approvals of avelumab with axitinib (JAVELIN Renal
101) and pembrolizumab with axitinib (KEYNOTE-426) as first-line
treatment for advanced RCC (13:24)
Comparison of cellular distribution, activity and tolerability
of anti-PD-1 versus PD-L1 antibodies (14:14)
Similarities and differences in clinical outcomes among the
JAVELIN Renal 101 (avelumab/axitinib) and KEYNOTE-426
(pembrolizumab/axitinib) trials (19:01)
Indirect comparison of the efficacy and tolerability of
nivolumab/ipilimumab versus avelumab/axitinib and
pembrolizumab/axitinib (26:35)
Importance of educating patients and community practitioners on
the distinction between immune checkpoint inhibitor- and
chemotherapy-related side effects (30:55)
Choosing among newly approved first-line therapeutic options
for mRCC (ie, avelumab/axitinib, pembrolizumab/axitinib,
nivolumab/ipilimumab); factors influencing whether to use a VEGF
tyrosine kinase inhibitor (32:45)
Perspective on the results of the Phase III IMmotion151 trial:
Atezolizumab with bevacizumab versus sunitinib in patients with
previously untreated mRCC (37:16)
Ongoing investigation of anti-PD-1/PD-L1 antibody-based therapy
in the (neo)adjuvant settings (41:17)
Toward increasing cure rates for patients with RCC (46:09)
Approach for patients with no evidence of disease after
nephrectomy (50:36)
Predictors of benefit with immune checkpoint inhibitors and
anti-angiogenic agents (53:16)
Case (Dr Choueiri): A man in his mid-60s with
clear cell mRCC who receives nivolumab/ipilimumab and for whom
nivolumab is held briefly because of a number of rare
immune-related AEs ultimately attains a durable near CR
(57:50)
Clinical experience with and management of rare immune-related
AEs in patients receiving checkpoint inhibitors (1:01:11)
Case (Prof Powles): A woman in her early 30s
with newly diagnosed intermediate-risk mRCC receives
nivolumab/ipilimumab (1:09:02)
Case (Prof Powles): A man in his late 60s with
intermediate-risk, clear cell mRCC experiences low-grade immune
checkpoint inhibitor-associated side effects with
nivolumab/ipilimumab (1:15:06)
Case (Dr Choueiri): A man in his mid-50s with
clear cell mRCC receives avelumab/axitinib on a clinical trial
(1:18:11)
Choosing between pembrolizumab/axitinib and avelumab/axitinib
(1:23:18)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.